Avanos Medical Earnings Call Transcripts
Fiscal Year 2026
-
Streamlined operations and divested underperforming assets, focusing on Specialty Nutrition and Pain Management for mid-single-digit growth. Successfully mitigated tariff risks, exceeded 2025 financial targets, and set a $1 billion revenue goal by 2030, supported by innovation and targeted acquisitions.
-
Management outlined a focused strategy for long-term growth, emphasizing operational efficiency, global expansion, and targeted M&A. Specialty nutrition and pain management segments are driving revenue, with new products and tariff mitigation supporting future growth.
Fiscal Year 2025
-
Solid 2025 results exceeded revised guidance, with strong growth in SNS and PM&R segments and successful portfolio reshaping. 2026 guidance anticipates continued organic growth, margin improvement in the second half, and full China exit for syringe manufacturing by June.
-
Q3 delivered double-digit organic growth in strategic segments, raised full-year guidance, and completed key portfolio moves including the Nexus Medical acquisition and HA divestiture. Cost savings and tariff mitigation efforts are underway, with strong liquidity supporting future M&A.
-
Second quarter saw strong organic growth in core segments, robust demand, and the divestiture of the HA product line. Full-year revenue and EPS guidance were reaffirmed despite tariff and macroeconomic headwinds, with continued focus on transformation and cost management.
-
Leadership changes and organizational restructuring are driving efficiency and growth, with a strong focus on innovation, premiumization, and global supply chain improvements. Despite tariff headwinds and slower category growth, margins have rebounded, and investments in brands and new products remain robust.
-
Q1 2025 saw strong sales growth in Specialty Nutrition Systems and solid progress in Pain Management and Recovery, with organic sales up 2.8% and robust cash flow. Tariff-related costs and executive changes led to a lower adjusted EPS outlook, but full-year revenue guidance remains unchanged.
Fiscal Year 2024
-
Q4 and full-year results showed strong organic growth in Enteral Feeding and solid free cash flow, offset by a significant impairment charge and ongoing pricing pressure in the HA business. 2025 guidance anticipates stable sales, margin pause, and continued focus on transformation and M&A.
-
Leadership changes and transformation efforts continued, with Q3 sales at $170M and adjusted EPS of $0.36. Digestive health outperformed, while pain management lagged due to supply issues. Q4 guidance calls for $175–$180M revenue and improved margins.
-
Q2 2024 saw 2.6% organic sales growth, margin expansion, and strong Digestive Health and Pain Management performance. Guidance for 2024 and 2025 was reaffirmed, with transformation priorities and cost management supporting improved profitability.